Duane Hassane

Company: AstraZeneca

Job title: Head of Translational Omics, Hematology R&D

Seminars:

Translating MRD Success in Hematologic Cancers to Solid Tumors to Expand MRD Impact & Accelerate Clinical Trials 2:30 pm

Exploring the role of minimal residual disease (MRD) in enhancing treatment strategies for hematologic cancers Leveraging MRD insights to optimize personalized therapies, improving patient outcomes and reducing relapse risks Discussing cutting-edge approaches to MRD detection and their impact on clinical decision-making in hematologic cancer management HematologyRead more

day: Conference Day 1